MedTrace Logo

Pharmacotherapy and Intensive Treatment - 2

NCT00000218 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 353

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Conditions

  • Cocaine-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Carbamazepine

Sponsors & Collaborators

  • VA Office of Research and Development

    collaborator FED

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • William Haning, M.D. · University of Kansas

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000218 on ClinicalTrials.gov